NCT07140484 Sotatercept in Pulmonary Arterial Hypertension
| NCT ID | NCT07140484 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of Alberta |
| Condition | Pulmonary Artery Hypertension |
| Study Type | INTERVENTIONAL |
| Enrollment | 27 participants |
| Start Date | 2025-10-06 |
| Primary Completion | 2029-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 27 participants in total. It began in 2025-10-06 with a primary completion date of 2029-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to determine whether sotatercept is effective in improving diffusing capacity in patients with pulmonary arterial hypertension. Participants will be asked to: * Take Sotatercept every 21 days (±3 days) * Each participant will be enrolled in the study for 29 Weeks * Visit the clinic 18 times * Have a physical exam * Perform assessments of lung function and exercise tests * Have an ultrasound of their heart * Have blood draws done at regular intervals The main objectives of the study are: Primary objective: To assess whether sotatercept will improve recruitment of diffusing membrane capacity (DM) with exercise. Secondary objective: To identify components of the diffusing capacity that respond to treatment with sotatercept in pulmonary arterial hypertension.
Eligibility Criteria
Eligible participants must meet all of the following inclusion criteria to be enrolled in the study: 1. Age ≥ 18 years. 2. Documented diagnostic right heart catheterization (RHC) at any time prior to screening confirming the diagnosis of PAH Group 1 in any of the following subtypes: * Idiopathic PAH * Heritable PAH * Drug/toxin-induced PAH * PAH associated with CTD * PAH associated with simple, congenital systemic-to-pulmonary shunts at least 1 year following repair. 3. Symptomatic PAH classified as WHO FC II or III. 4. On stable doses of ≥2 background PAH therapies for at least 60 days prior to screening; for infusion prostacyclins, dose adjustment within 10% of the optimal dose is allowed per medical practice. Patients on 1 background PAH therapy are eligible if there is documented intolerance or contraindication to use of the other 2 classes (e.g. liver enzyme elevation while taking an ERA). 5. Females of childbearing potential must: * Have a negative urine or serum pregnancy tests as verified by the investigator prior to starting study therapy. * If sexually active, have used, and agree to use highly effective contraception without interruption during the study (including dose interruptions), and for 16 weeks (112 days) after discontinuation of study treatment. * Refrain from breastfeeding a child or donating blood, eggs, or ovum for the duration of the study and for at least 16 weeks (112 days) after the last dose of study treatment. 6. Male participants must: * Agree to use a condom, defined as a male latex condom or nonlatex condom NOT made out of natural (animal) membrane (e.g., polyurethane), during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 16 weeks (112 days) following investigational product discontinuation, even if he has undergone a successful vasectomy. * Refrain from donating blood or sperm for the duration of the study and for 16 weeks (112 days) after the last dose of study treatment 7. Ability to adhere to study visit schedule and understand and comply with all protocol requirements. 8. Ability to understand and provide written informed consent. Exclusion Criteria 1. 1\. Diagnosis of pulmonary hypertension WHO Groups 2, 3, 4, or 5 2. Musculoskeletal limitation that precludes participation in cycle ergometry 3. Resting oxygen saturation \< 88%. (Note: patients on oxygen can be included in the study if they can maintain a resting saturation of ≥ 88 % after 3 minutes off oxygen). 4. Diagnosis of the following PAH Group 1 subtypes: human immunodeficiency virus (HIV)-associated PAH and PAH associated with portal hypertension, schistosomiasis-associated PAH and pulmonary veno-occlusive disease. 5. Hemoglobin (Hgb) at screening above the gender-specific upper limit of normal (ULN), per local laboratory test. 6. Baseline platelet count \< 50,000/mm3 (\< 50.0 × 109/L) in the enrollment period. 7. Uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure \> 160 mmHg or sitting diastolic blood pressure \> 100 mmHg during a screening visit after a period of rest. 8. Baseline systolic blood pressure \< 90 mmHg at screening. 9. Pregnant or breastfeeding women. 10. Any of the following clinical laboratory values at the screening visit: * Estimated glomerular filtration rate (eGFR) \< 30 mL/min/m2 (as defined by the Modification of Diet in Renal Disease \[MDRD\] equation) * Serum alanine aminotransferase, aspartate aminotransferase, or total bilirubin levels \> 3 × ULN (bilirubin criterion waived if there is a documented history of Gilbert's syndrome). 11. Currently enrolled in or have completed any other investigational product study within 30 days for small-molecule drugs or within 5 half-lives for biologics prior to the date of signed informed consent. 12. History of full pneumonectomy. 13. Pulmonary function test (PFT) values of forced vital capacity (FVC) \< 60% predicted and/or FEV1/FVC \< lower limit of normal at the screening visit or within 6 months prior to the screening visit. 14. Smoking history of ≥ 20 pack-years or any tobacco smoking or vaping within the previous 3 months. 15. Body mass index ≥ 40 kg/m2. 16. Planned initiation of an exercise program for cardiopulmonary rehabilitation during the study (participants who are stable in the maintenance phase of a program and who will continue for the duration of the study are eligible). 17. Known history of portal hypertension or chronic liver disease, including hepatitis B and/or hepatitis C (with evidence of recent infection and/or active virus replication), defined as mild to severe hepatic impairment (Child-Pugh Class A-C). 18. History of restrictive, constrictive, or congestive cardiomyopathy. 19. History of atrial septostomy within 180 days prior to the screening visit. 20. Electrocardiogram (ECG) with Fridericia's corrected QT interval (QTcF) \> 500 ms during the Screening Period 21. Personal or family history of long QT syndrome (LQTS) or sudden cardiac death. 22. Left ventricular ejection fraction \< 45% on historical echocardiogram within 6 months prior to the screening visit. 23. Any symptomatic coronary disease events (prior myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, or cardiac anginal chest pain) within 6 months prior to the screening visit. Note: Anginal pain can be ignored as an exclusion criterion if coronary angiography shows no obstructions. 24. Cerebrovascular accident within 3 months prior to the Screening Visit. 25. Significant mitral or aortic valve dysfunction (greater than moderate mitral regurgitation or aortic regurgitation, or greater than mild mitral stenosis or aortic stenosis). 26. Received intravenous inotropes (e.g., dobutamine, dopamine, norepinephrine, vasopressin) within 30 days prior to the screening visit. 27. Known hypersensitivity to sotatercept or to any ingredient in the formulation or component of the container.
Contact & Investigator
Jason Weatherald, MD
PRINCIPAL INVESTIGATOR
University of Alberta
Frequently Asked Questions
Who can join the NCT07140484 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pulmonary Artery Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07140484 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07140484 currently recruiting?
Yes, NCT07140484 is actively recruiting participants. Contact the research team at fuhr@ualberta.ca for enrollment information.
Where is the NCT07140484 trial being conducted?
This trial is being conducted at Edmonton, Canada.
Who is sponsoring the NCT07140484 clinical trial?
NCT07140484 is sponsored by University of Alberta. The principal investigator is Jason Weatherald, MD at University of Alberta. The trial plans to enroll 27 participants.